Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“

por Pappagallo, Marco, Inturrisi, Charles E., Manfredi, Paolo L.
Publicado 2022

Does transdermal fentanyl work in patients with low BMI? Patient‐reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl

por Moryl, Natalie, Bokhari, Ali, Griffo, Yvona, Hadler, Rachel, Koranteng, Lauren, Filkins, Alexandra, Zheng, Tianyu, Horn, Susan D., Inturrisi, Charles E.
Publicado 2019

The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin

por Bettini, Ezio, De Martin, Sara, Mattarei, Andrea, Pappagallo, Marco, Stahl, Stephen M., Bifari, Francesco, Inturrisi, Charles E., Folli, Franco, Traversa, Sergio, Manfredi, Paolo L.
Publicado 2022

REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study

por De Martin, Sara, Gabbia, Daniela, Folli, Franco, Bifari, Francesco, Fiorina, Paolo, Ferri, Nicola, Stahl, Stephen, Inturrisi, Charles E., Pappagallo, Marco, Traversa, Sergio, Manfredi, Paolo L.
Publicado 2021

REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats

por Henningfield, Jack, Gauvin, David, Bifari, Francesco, Fant, Reginald, Shram, Megan, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Pappagallo, Marco, Inturrisi, Charles, Folli, Franco, Traversa, Sergio, Manfredi, Paolo L.
Publicado 2022

Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling

por Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Bettini, Ezio, Pani, Luca, Guidetti, Clotilde, Folli, Franco, de Somer, Marc, Traversa, Sergio, Inturrisi, Charles E., Pappagallo, Marco, Gentilucci, Marco, Alimonti, Andrea, Fava, Maurizio, Manfredi, Paolo L.
Publicado 2022

Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors

por Bettini, Ezio, Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Sgrignani, Jacopo, Carignani, Corrado, Nola, Selena, Locatelli, Patrizia, Pappagallo, Marco, Inturrisi, Charles E., Bifari, Francesco, Cavalli, Andrea, Alimonti, Andrea, Pani, Luca, Fava, Maurizio, Traversa, Sergio, Folli, Franco, Manfredi, Paolo L.
Publicado 2022

Esmethadone-HCl (REL-1017): a promising rapid antidepressant

por Fava, Maurizio, Stahl, Stephen M., De Martin, Sara, Mattarei, Andrea, Bettini, Ezio, Comai, Stefano, Alimonti, Andrea, Bifari, Francesco, Pani, Luca, Folli, Franco, Guidetti, Clotilde, Furlan, Alberto, Sgrignani, Jacopo, Locatelli, Patrizia, Cavalli, Andrea, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Pappagallo, Marco, Manfredi, Paolo L.
Publicado 2023

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users

por Shram, Megan J., Henningfield, Jack E., Apseloff, Glen, Gorodetzky, Charles W., De Martin, Sara, Vocci, Frank L., Sapienza, Frank L., Kosten, Thomas R., Huston, Jeff, Buchhalter, August, Ashworth, Judy, Lanier, Ryan, Folli, Franco, Mattarei, Andrea, Guidetti, Clotilde, Comai, Stefano, O’Gorman, Cedric, Traversa, Sergio, Inturrisi, Charles E., Manfredi, Paolo L., Pappagallo, Marco
Publicado 2023